Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc. reported a strong finish to 2025, with fourth-quarter net revenue of $128.6 million, including $91.2 million from DefenCath and $37.4 million from the newly acquired Melinta portfolio, up sharply from $31.2 million in the prior-year quarter.
For full-year 2025, total revenue rose to $311.7 million and pro forma revenue, assuming a full year of Melinta, reached $401.3 million. The company generated net income of $163.1 million, or $2.04 per diluted share, reversing a $17.9 million loss in 2024, and delivered adjusted EBITDA of $77.2 million in Q4 2025. Operating expenses roughly doubled as CorMedix absorbed Melinta and invested in DefenCath and late-stage studies, while cash, cash equivalents and short-term investments totaled $148.5 million as of December 31, 2025.
CorMedix Inc. insider filing shows a new equity award to its Chief Legal Officer. Beth Zelnick Kaufman received 36,006 shares of common stock on February 4, 2026 at a price of $0.00, following achievement of performance stock unit (PSU) goals for the first of three performance periods.
The PSUs were originally granted on January 2, 2025 and remain subject to additional time-based vesting conditions before fully vesting. After this award, she beneficially owns 269,108 shares of CorMedix common stock directly.
CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported an equity-related award linked to performance stock units. On 02/04/2026, she acquired 36,006 shares of CorMedix common stock at a reported price of $0.00, increasing her beneficial ownership to 278,539 directly held shares.
The filing explains this reflects achievement of performance stock units granted on January 2, 2025, after the Compensation Committee determined that performance conditions for the first of three performance periods were met. These units remain subject to additional time-based vesting requirements for Hurlburt.
CorMedix Inc. reported an equity award to its Chief Executive Officer and director Joseph Todisco. On February 4, 2026, he acquired 77,156 shares of common stock at $0.00 per share, following the achievement of performance stock units for the first of three performance periods granted on January 2, 2025.
After this transaction, Todisco beneficially owned 774,749 shares of CorMedix common stock, held directly. The performance stock units remain subject to time-based vesting conditions that must be satisfied by the reporting person before full vesting.
CorMedix Inc. Chief Financial Officer Susan Blum reported equity compensation and related share withholding transactions. On 01/23/2026, she was granted 72,820 restricted stock units, each representing one share of CorMedix common stock at a stated price of $0.00.
The restricted stock units vest 1/4 on the grant date and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant. On the same date, 9,767 shares of common stock were disposed of at $7.27 per share in a transaction coded "F," typically indicating shares withheld to cover taxes. After these transactions, Blum directly owned 132,739 shares of CorMedix common stock.
CorMedix Inc.'s Chief Legal Officer Beth Zelnick Kaufman reported equity compensation activity in the company’s common stock. On 01/23/2026 she received an award of 72,820 restricted stock units at a price of $0.00 per unit, each representing one share of common stock.
The restricted stock units vest 25% on the grant date and, subject to continued employment, 25% on each of the first, second, and third anniversaries of the grant date. On the same day, 8,803 shares were withheld at $7.27 per share, typically for tax obligations, leaving her with 233,102 directly owned shares after the reported transactions.
CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported equity compensation and a related share sale. On 01/23/2026 she received 93,010 shares of common stock for $0.00 per share as a grant of restricted stock units that convert into common stock.
The restricted stock units vest 1/4 at grant and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant date. On the same day, 10,778 shares of common stock were disposed of at $7.27 per share, typically reflecting shares withheld or sold to cover taxes, leaving her with 242,533 directly owned shares.
CorMedix Inc.’s Chief Executive Officer and director Joseph Todisco reported an equity award and related share transaction. On 01/23/2026, he received 225,900 restricted stock units, each representing one share of common stock, at a price of $0.00.
The restricted stock units vest 1/4 on the grant date and, subject to continued employment, 1/4 on each of the first, second, and third anniversaries of the grant. On the same date, a second transaction labeled code F covered 27,306 shares at $7.27 per share, leaving Todisco with 697,593 common shares held directly.
CorMedix Inc. director Myron Kaplan received an equity grant of 30,453 restricted stock units on January 26, 2026. The Form 4 shows these RSUs were awarded at a price of $0.00 per unit and will vest in full on January 26, 2027, subject to his continued service through that date.
Following this grant, Kaplan directly beneficially owned 231,487 shares of CorMedix common stock. The filing also notes additional indirect holdings of 20,000 shares held by his spouse and 10,000 shares held by his spouse as guardian for grandchildren, for which he expressly disclaims beneficial ownership.
CorMedix Inc. director Janet Dillione received an equity grant of 30,453 shares of common stock in the form of restricted stock units. The units were issued on January 26, 2026 at a stated price of $0.00 per share and represent a right to receive an equal number of common shares.
The restricted stock units will vest in full on January 26, 2027, conditioned on continued service through that date. Following this grant, Dillione beneficially owns 68,926 shares of CorMedix common stock in direct ownership.